We have recently shown that the sphingolipid ceramide activates PKR to induce cell death in AML and synergizes with the Bcl-2 inhibitor venetoclax in vitro and in patient derived xenografts models of AML [21]. The gene discussed is BCL2; the disease is acute myeloid leukemia.